Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 3/20 | 0.77 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | SHBG | P04278 | 3/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.68 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418766 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418928 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL6874636 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418641 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL6905401 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418980 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL6884657 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1419111 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418644 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG | |
| SCHEMBL1418792 | 1.00 | G6PD (0.77) | G6PDGPBAR1LMNACYP3A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910571-B2 | 3 beta -hydroxy-16 alpha -fluoro-17 beta -aminoandrost-5-ene; immunostimulant, antiinflammatory agent; neutropenia, infections, blood cell deficiencies; interleukin, tumor necrosis factor, macrophage inflammatory protein, transforming growth factor, cyclooxygenase, and lipoxygenase inhibitor | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7547687-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7482334-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080090791-A1 | Cystic fibrosis treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070275937-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275938-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275938-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | G6PD 317/4885GPBAR1 184/4885LMNA 3176/4885 |
| US-20070275937-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | G6PD 317/4885GPBAR1 184/4885LMNA 3176/4885 |
| US-20080090791-A1 | Cystic fibrosis treatment methods | HSD3B1, ELANE, CFTR | G6PD 440/4885GPBAR1 218/4885LMNA 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.